AVITA Medical, Inc. (RCEL)
10.73
-0.03
(-0.28%)
USD |
NASDAQ |
Sep 03, 13:48
AVITA Medical Cash from Investing (Quarterly) : 3.947M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.947M |
| March 31, 2026 | 2.041M |
| December 31, 2025 | -0.019M |
| September 30, 2025 | -5.267M |
| June 30, 2025 | 7.196M |
| March 31, 2025 | 10.77M |
| December 31, 2024 | 1.650M |
| September 30, 2024 | 7.736M |
| June 30, 2024 | 12.46M |
| March 31, 2024 | 15.07M |
| December 31, 2023 | -56.07M |
| Date | Value |
|---|---|
| September 30, 2023 | 20.91M |
| June 30, 2023 | 17.94M |
| March 31, 2023 | 18.79M |
| December 31, 2022 | -2.700M |
| September 30, 2022 | -7.833M |
| June 30, 2022 | 14.82M |
| March 31, 2022 | -22.60M |
| June 30, 2021 | -0.1867M |
| March 31, 2021 | -0.3835M |
| December 31, 2020 | -0.3461M |
| September 30, 2020 | -0.296M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | -62.66M |
| Iovance Biotherapeutics, Inc. | -74.05M |
| Editas Medicine, Inc. | -29.80M |
| Arcus Biosciences, Inc. | 52.00M |
| Recursion Pharmaceuticals, Inc. | -1.959M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.630M |
| Cash from Financing (Quarterly) | 0.5013M |
| Free Cash Flow | -25.21M |
| Free Cash Flow Per Share (Quarterly) | -0.1217 |
| Free Cash Flow to Equity (Quarterly) | -4.103M |
| Free Cash Flow to Firm (Quarterly) | -2.272M |
| Free Cash Flow Yield | -7.83% |